Diretriz atualizada da IDSA para Covid-19 agora apoia o uso de plasma convalescente em pacientes ambulatoriais com COVID-19 leve a moderada sob alto risco de progressão para doença grave.

IDSA Guidelines on the Treatment and Management of Patients with COVID-19 – Infectious Diseases Society of America

Conteúdo relacionado: [Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

Comentário no Twitter

Update Alert: Revised recommendation on the use of #convalescentplasma in ambulatory patients w/ COVID-19 at high risk of progression to severe disease w/ no other treatment options.

📄: https://t.co/YRCxtdilXT#COVID19Guidelines @JGPharmD @adarsh_bhimraj @RMKGandhi @ShohamTxID pic.twitter.com/KpXnywH362

— IDSA (@IDSAInfo) February 8, 2022